Skip to main content

Table 1 Patient, disease and treatment characteristics

From: First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer

  Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6
Sex F M M F M F
Age at diagnosis 56 41 32 74 32 39
Year of diagnosis 2005 2013 2006 2016 2004 2017
Tumour type AdCC AdCC AdCC Adenocarcinoma NOS Acinic cell carcinoma AdCC
Tumour site Hard palate Parotid Cheek mucosa Parotid Parotid Submandibular gland
Treatment Local excision Local excision + radiotherapy Local excision + radiotherapy Palliative radiotherapy Local excision + radiotherapy Local excision + radiotherapy
Disease
Locoregional recurrence Parapharyngeal, intracranial Parapharyngeal, lymphatic
Distant metastases Lung, Liver - Lung, Bone (vertebra) Bone (skull, vertebra) Lymphatic (inguinal), Lung, Bone (vertebra) -
Completed ‘conventional’ palliative treatment None None Chemotherapy (CAP), radiotherapy Radiotherapy Chemotherapy (CAP), radiotherapy Chemotherapy (CAP), radiotherapy
PSMA expression on IHC (%) 5 30 N/A 30 95 30
SUVmax VOI before treatment 3.5 lung 6.5 intracranial 10.2 pelvis 12.5 pelvis 9.7 pelvis 7.0 parapharyngeal
Treatment
Diagnosis to 177Lu-PSMA (years) 12 6 12 1 14 2
No. cycles 4 4 2 1 2 2
SUVmax VOI after treatment N/A 4.5 N/A N/A 17.6 9.4
Reason of discontinuation End of protocol End of protocol Disease progression, adverse effects Demotivation due to side-effects Disease progression Disease progression
Side effects
Side effects (CTCAE grade) Fatigue (2)
Dyspnoea (2)
Nausea (1)
Fatigue (1)
Nausea (1)
Vomiting (1)
Xerostomia (1)
Fatigue (1)
Bone pain (2)
Thrombocytopenia (3)
Fatigue (1)
Xerostomia (1)
Fatigue (1)
Xerostomia (1)
Bone pain (2)
Fatigue (1)
Xerostomia (2)
Response
Clinical Less dyspnoea, less fatigue Improved facial expression and sensibility, less fatigue Disease progression N/A Significant pain relief (6 weeks) Diminution of facial nerve palsy, pain relief
Radiological Stable lung lesions, minimal progression of liver metastases Stable disease, decrease SUVmax Disease progression N/A Disease progression Disease progression
Follow-up
(months after first treatment)
Deceased
(7)
Alive with disease
(36)
Deceased
(3)
Deceased
(5)
Deceased
(6)
Deceased
(9)
  1. AdCC: Adenoid cystic carcinoma; CAP: cyclophosphamide, adriamycin, cisplatin; PSMA: prostate-specific membrane antigen; IHC: immunohistochemistry; N/A: not available; CTCAE: common terminology criteria for adverse events